Bausch + Lomb Corporation (BLCO)
After hours:
| Previous close | 17.80 |
| Open | 17.74 |
| Bid | 18.39 x 1400 |
| Ask | 18.51 x 2200 |
| Day's range | 17.56 - 18.57 |
| 52-week range | 13.16 - 18.58 |
| Volume | |
| Avg. volume | 695,446 |
| Market cap | 6.552B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Investing.com
Bausch + Lomb explores sale amid parent company's debt woes - report
Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with significant debt, as per a Financial Times report. The move has faced opposition from lenders, including Apollo Global Management (NYSE:APO). “This (sale) makes sense to us given the steep valuation discount between BLCO and its closest eye care peers,” said analysts from Wells Fargo in a note.
- Simply Wall St.
Bausch + Lomb Insider Ups Holding During Year
From what we can see, insiders were net buyers in Bausch + Lomb Corporation's ( NYSE:BLCO ) during the past 12 months...
- GuruFocus.com
Insider Buying: CEO Brent Saunders Acquires Shares of Bausch & Lomb Corp
The transaction was filed with the SEC and indicates a strong signal of confidence from the insider. Following this acquisition, the insider now owns 627,419 shares of Bausch & Lomb Corp. Bausch & Lomb Corp is primarily engaged in the development, manufacture, and marketing of a range of pharmaceutical, medical device, and over-the-counter products, particularly in eye health.
